{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T12:17:15Z","timestamp":1774441035235,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,9,7]],"date-time":"2012-09-07T00:00:00Z","timestamp":1346976000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1245\/s10434-012-2640-8","type":"journal-article","created":{"date-parts":[[2012,9,6]],"date-time":"2012-09-06T13:42:29Z","timestamp":1346938949000},"page":"811-818","source":"Crossref","is-referenced-by-count":50,"title":["Microinvasive Breast Cancer: ER, PR, and HER-2\/neu Status and Clinical Outcomes after Breast-Conserving Therapy or Mastectomy"],"prefix":"10.1245","volume":"20","author":[{"given":"Danielle N.","family":"Margalit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meera","family":"Sreedhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul L.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehra","family":"Golshan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth A.","family":"Overmoyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay R.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane E.","family":"Brock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,9,7]]},"reference":[{"key":"2640_CR1","volume-title":"AJCC cancer staging manual","author":"American Cancer Society","year":"2002","unstructured":"American Cancer Society. AJCC cancer staging manual, 6th ed. New York: Springer-Verlag, 2002.","edition":"6"},{"key":"2640_CR2","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1002\/cncr.10451","volume":"94","author":"I Mascarel de","year":"2002","unstructured":"de Mascarel I, MacGrogan G, Mathoulin-Pelissier S, Soubeyran I, Picot V, Coindre JM. Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas. Cancer. 2002;94:2134\u201342.","journal-title":"Cancer."},{"key":"2640_CR3","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s10434-000-0656-y","volume":"7","author":"NQ Mirza","year":"2000","unstructured":"Mirza NQ, Vlastos G, Meric F, et al. Ductal carcinoma-in situ: long-term results of breast-conserving therapy. Ann Surg Oncol. 2000;7:656\u201364.","journal-title":"Ann Surg Oncol."},{"key":"2640_CR4","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/(SICI)1097-0142(20000315)88:6<1403::AID-CNCR18>3.0.CO;2-S","volume":"88","author":"RF Padmore","year":"2000","unstructured":"Padmore RF, Fowble B, Hoffman J, Rosser C, Hanlon A, Patchefsky AS. Microinvasive breast carcinoma: clinicopathologic analysis of a single institution experience. Cancer. 2000;88:1403\u20139.","journal-title":"Cancer."},{"key":"2640_CR5","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/1097-0142(19910315)67:6<1498::AID-CNCR2820670606>3.0.CO;2-I","volume":"67","author":"D Rosner","year":"1991","unstructured":"Rosner D, Lane WW, Penetrante R. Ductal carcinoma in situ with microinvasion. A curable entity using surgery alone without need for adjuvant therapy. Cancer. 1991;67:1498\u2013503.","journal-title":"Cancer."},{"key":"2640_CR6","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1001\/archsurg.1986.01400110095016","volume":"121","author":"ME Schuh","year":"1986","unstructured":"Schuh ME, Nemoto T, Penetrante RB, Rosner D, Dao TL. Intraductal carcinoma. Analysis of presentation, pathologic findings, and outcome of disease. Arch Surg. 1986;121:1303\u20137.","journal-title":"Arch Surg."},{"key":"2640_CR7","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1002\/(SICI)1097-0142(19980615)82:12<2382::AID-CNCR12>3.0.CO;2-L","volume":"82","author":"SA Silver","year":"1998","unstructured":"Silver SA, Tavassoli FA. Mammary ductal carcinoma in situ with microinvasion. Cancer. 1998;82:2382\u201390.","journal-title":"Cancer."},{"key":"2640_CR8","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/0360-3016(92)90900-3","volume":"23","author":"LJ Solin","year":"1992","unstructured":"Solin LJ, Fowble BL, Yeh IT, et al. Microinvasive ductal carcinoma of the breast treated with breast-conserving surgery and definitive irradiation. Int J Radiat Oncol Biol Phys. 1992;23:961\u20138.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2640_CR9","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1001\/archsurg.1990.01410220082011","volume":"125","author":"JH Wong","year":"1990","unstructured":"Wong JH, Kopald KH, Morton DL. The impact of microinvasion on axillary node metastases and survival in patients with intraductal breast cancer. Arch Surg. 1990;125:1298\u2013301.","journal-title":"Arch Surg."},{"key":"2640_CR10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijrobp.2010.08.027","volume":"82","author":"RR Parikh","year":"2012","unstructured":"Parikh RR, Haffty BG, Lannin D, Moran MS. Ductal carcinoma in situ with microinvasion: prognostic implications, long-term outcomes, and role of axillary evaluation. Int J Radiat Oncol Biol Phys. 2012;82:7\u201313.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2640_CR11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejrad.2008.09.037","volume":"73","author":"CC Vieira","year":"2010","unstructured":"Vieira CC, Mercado CL, Cangiarella JF, Moy L, Toth HK, Guth AA. Microinvasive ductal carcinoma in situ: clinical presentation, imaging features, pathologic findings, and outcome. Eur J Radiol. 2010;73:102\u20137.","journal-title":"Eur J Radiol."},{"key":"2640_CR12","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1186\/1471-2407-10-557","volume":"10","author":"JH Kwon","year":"2010","unstructured":"Kwon JH, Kim YJ, Lee KW, et al. Triple negativity and young age as prognostic factors in lymph node\u2013negative invasive ductal carcinoma of 1\u00a0cm or less. BMC Cancer. 2010;10:557.","journal-title":"BMC Cancer."},{"key":"2640_CR13","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2007.14.5565","volume":"26","author":"M Kyndi","year":"2008","unstructured":"Kyndi M, Sorensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008;26:1419\u201326.","journal-title":"J Clin Oncol."},{"key":"2640_CR14","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2007.14.4287","volume":"26","author":"PL Nguyen","year":"2008","unstructured":"Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26:2373\u20138.","journal-title":"J Clin Oncol."},{"key":"2640_CR15","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ijrobp.2009.12.011","volume":"77","author":"JM Albert","year":"2010","unstructured":"Albert JM, Gonzalez-Angulo AM, Guray M, et al. Estrogen\/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. Int J Radiat Oncol Biol Phys. 2010;77:1296\u2013302.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2640_CR16","doi-asserted-by":"crossref","first-page":"5700","DOI":"10.1200\/JCO.2009.23.2025","volume":"27","author":"AM Gonzalez-Angulo","year":"2009","unstructured":"Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1\u00a0cm or smaller. J Clin Oncol. 2009;27:5700\u20136.","journal-title":"J Clin Oncol."},{"key":"2640_CR17","doi-asserted-by":"crossref","first-page":"e581","DOI":"10.1016\/j.ijrobp.2011.08.015","volume":"82","author":"LM Halasz","year":"2012","unstructured":"Halasz LM, Sreedhara M, Chen YH, et al. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ. Int J Radiat Oncol Biol Phys. 2012;82:e581\u20136.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2640_CR18","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/jnci\/djq101","volume":"102","author":"K Kerlikowske","year":"2010","unstructured":"Kerlikowske K, Molinaro AM, Gauthier ML, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst. 2010;102:627\u201337.","journal-title":"J Natl Cancer Inst."},{"key":"2640_CR19","first-page":"290","volume":"12","author":"R Stackievicz","year":"2010","unstructured":"Stackievicz R, Paran H, Bernheim J, et al. Prognostic significance of HER-2\/neu expression in patients with ductal carcinoma in situ. Isr Med Assoc J. 2010;12:290\u20135.","journal-title":"Isr Med Assoc J."},{"key":"2640_CR20","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1524-4741.2008.00594.x","volume":"14","author":"AA Guth","year":"2008","unstructured":"Guth AA, Mercado C, Roses DF, Darvishian F, Singh B, Cangiarella JF. Microinvasive breast cancer and the role of sentinel node biopsy: an institutional experience and review of the literature. Breast J. 2008;14:335\u20139.","journal-title":"Breast J."},{"key":"2640_CR21","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1245\/ASO.2003.04.009","volume":"10","author":"M Intra","year":"2003","unstructured":"Intra M, Zurrida S, Maffini F, et al. Sentinel lymph node metastasis in microinvasive breast cancer. Ann Surg Oncol. 2003;10:1160\u20135.","journal-title":"Ann Surg Oncol."},{"key":"2640_CR22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.5858\/133.1.31","volume":"133","author":"A Grin","year":"2009","unstructured":"Grin A, Horne G, Ennis M, O\u2019Malley FP. Measuring extent of ductal carcinoma in situ in breast excision specimens: a comparison of 4 methods. Arch Pathol Lab Med. 2009;133:31\u20137.","journal-title":"Arch Pathol Lab Med."},{"key":"2640_CR23","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1097\/01.MP.0000038462.62634.B1","volume":"15","author":"EK Latta","year":"2002","unstructured":"Latta EK, Tjan S, Parkes RK, O\u2019Malley FP. The role of HER2\/neu overexpression\/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol. 2002;15:1318\u201325.","journal-title":"Mod Pathol."},{"key":"2640_CR24","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/j.1365-2559.2006.02403.x","volume":"48","author":"K Park","year":"2006","unstructured":"Park K, Han S, Kim HJ, Kim J, Shin E. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology. 2006;48:702\u20137.","journal-title":"Histopathology."},{"key":"2640_CR25","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.breast.2006.08.002","volume":"16","author":"G Zavagno","year":"2007","unstructured":"Zavagno G, Belardinelli V, Marconato R, et al. Sentinel lymph node metastasis from mammary ductal carcinoma in situ with microinvasion. Breast. 2007;16:146\u201351.","journal-title":"Breast."},{"key":"2640_CR26","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","volume":"25","author":"AC Wolff","year":"2007","unstructured":"Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118\u201345.","journal-title":"J Clin Oncol."},{"key":"2640_CR27","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1001\/jama.291.16.1972","volume":"291","author":"H Yaziji","year":"2004","unstructured":"Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004;291:1972\u20137.","journal-title":"JAMA."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-012-2640-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-012-2640-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-012-2640-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T10:48:15Z","timestamp":1643366895000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-012-2640-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,7]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["2640"],"URL":"https:\/\/doi.org\/10.1245\/s10434-012-2640-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,7]]}}}